Key result
HeartWare LVAD adverse events drop ~82% after the first 30 days post-implant.
Cohort (n=382)
Answers are grounded in this paper and cite their sources.
The HeartWare Ventricular Assist System (HVAD) provides significant improvements in survival and quality of life, and here, we seek to evaluate temporal differences in the adverse event (AE) rates. Patients (n = 382) in the ADVANCE bridge-to-transplant and continued access protocol trial were assessed for bleeding, cardiac arrhythmia, infection, ischemic and hemorrhagic stroke, and right heart failure during predetermined time periods (≤30, >30-180, >180-365, >365-730, >730-1,095 days) after HVAD implant. The Kaplan-Meier survival at 30 days, 6 months, 1, 2, and 3 years was 98%, 90%, 84%, 71%, and 63%, respectively. There were significantly fewer total AEs in days >30-180 (events per patient year [EPPY] = 5.34) compared with the first 30 days post HVAD implantation (EPPY = 30.36; p < 0.0001). The total AE rate in days >180-365 (EPPY = 4.09) was also significantly lower than the event rate in days >30-180 (EPPY = 5.34; p < 0.0001). Incidence of cardiac arrhythmias, infections, strokes, and right heart failure were highest immediately post implant and lower rates occurred after 6 months. After 1 year, all AEs exhibited stable rates that were comparable up to 3 years of support (all p > 0.05). This changing risk over time has clinically meaningful implications toward improving patient management.
No takes yet. Share an insight, caveat, or question.
Maltais et al. (2017) conducted a cohort in Heart failure bridged to transplant with HeartWare Left Ventricular Assist Device (n=382). HeartWare Ventricular Assist System (HVAD) implantation vs. Different post-implantation time intervals (≤30 days vs >30-180 days, >180-365 days, and up to 3 years) was evaluated on Total adverse event rates (events per patient year [EPPY]) across predetermined post-implant time periods (>30-180 days vs ≤30 days) (p=<0.0001). HeartWare LVAD support showed lower adverse event rates in days >30-180 vs the first 30 days, stabilizing after 1 year with 63% 3-year survival.
Synapse has enriched 10 related papers. Consider them for comparative context: